Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07132983) titled 'A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Verona Pharma plc
Condition:
Chronic Obstructive Pulmonary Disease
Intervention:
Drug: Ensifentrine 3 mg
Drug: Glycopyrrolate 42.5 mcg
Drug: Ens...